Talaris Therapeutics Inc. (TALS)
$2.75
$-271.25
(-99.00%)
As on 19-Oct-2023 19:52EDT
Market cap
$120 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-23 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-13.7
-
Face value
--
-
Shares outstanding
42,810,600
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Talaris Therapeutics (TALS)
| -97.3 | -99.1 | -99.1 | -98.9 | -- | -- | -- |
|
BSE Sensex*
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
|---|---|
|
Talaris Therapeutics (TALS)
| -93.3 |
|
S&P Small-Cap 600
| -17.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Talaris Therapeutics (TALS)
|
2.8 | 119.6 | 0.0 | -57.7 | -- | -40.8 | -- | 0.3 |
| 0.3 | 10.9 | 0.0 | -59.3 | -- | -131.8 | -- | 0.9 |
Shareholding Pattern
View DetailsAbout Talaris Therapeutics (TALS)
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc., in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in... developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. Read more
-
Pres, CEO, Sec. & Director
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA
-
Pres, CEO, Sec. & Director
Mr. Scott Requadt J.D., L.L.B., M.B.A., MBA
-
Headquarters
Louisville, KY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Talaris Therapeutics (TALS)
What is the current share price of Talaris Therapeutics Inc (TALS) Today?
The share price of Talaris Therapeutics Inc (TALS) is $2.75 (NASDAQ) as of 19-Oct-2023 19:52 EDT. Talaris Therapeutics Inc (TALS) has given a return of -98.88% in the last 1 years.
What is the current PB & PE ratio of Talaris Therapeutics Inc (TALS)?
Since, TTM earnings of Talaris Therapeutics Inc (TALS) is negative, P/E ratio is not available.
The P/B ratio of Talaris Therapeutics Inc (TALS) is 0.28 times as on 16-Nov-2023, a 94 discount to its peers’ median range of 4.42 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.06
|
0.02
|
|
2021
|
-12.91
|
2.56
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-0.06
|
0.02
|
What is the 52 Week High and Low of Talaris Therapeutics Inc (TALS)?
The 52-week high and low of Talaris Therapeutics Inc (TALS) are Rs -- and Rs -- as of 09-May-2026.
What is the market cap of Talaris Therapeutics Inc (TALS)?
Talaris Therapeutics Inc (TALS) has a market capitalisation of $ 120 Mln as on 16-Nov-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Talaris Therapeutics Inc (TALS)?
Before investing in Talaris Therapeutics Inc (TALS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.